Refractory Tumor clinical trials at University of California Health

2 in progress, 1 open to eligible people

Showing trials for

  • 9-ING-41 in Pediatric Patients with Refractory Malignancies.

    open to eligible people ages up to 22 years

    9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.

    at UCSF

  • STI-6643 in Subjects With Advanced Solid Tumors

    Sorry, not currently recruiting here

    This is a first-in-human, phase 1, open-label, dose-escalation study of STI-6643 administered by intravenous infusion in subjects with a relapsed/refractory advanced solid tumor.

    at UCSD

Our lead scientists for Refractory Tumor research studies include .

Last updated: